Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Hoffman

Showing results (811-820 of 814) with videos related to

Pageof 82
Sort By:
You have reached the last page of results.This site can display upto 814 results.
The EMBO Journal|June 30, 2025
Sphingosine simultaneously inhibits nuclear import and activates PP2A by binding importins and PPP2R1AVaishali Jayashankar, Peter Kubiniok, Alison N McCracken, et al.
Nature|August 23, 2002
Chemical investigation of hassium (element 108)Ch E Düllmann, W Brüchle, R Dressler, et al.
Cancer|February 11, 2004
A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignanciesPaul J Hesketh, Francis Arena, Dhimant Patel, et al.
Breast Cancer Research and Treatment|May 8, 2020
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015Peter H O'Donnell, Vassily Trubetskoy, Ashley Nurhussein-Patterson, et al.
Pageof 82

Showing results (811-820 of 814) with videos related to

Sort By:
Pageof 82
You have reached the last page of results.This site can display upto 814 results.
The EMBO Journal|June 30, 2025
Sphingosine simultaneously inhibits nuclear import and activates PP2A by binding importins and PPP2R1AVaishali Jayashankar, Peter Kubiniok, Alison N McCracken, et al.
Nature|August 23, 2002
Chemical investigation of hassium (element 108)Ch E Düllmann, W Brüchle, R Dressler, et al.
Cancer|February 11, 2004
A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignanciesPaul J Hesketh, Francis Arena, Dhimant Patel, et al.
Breast Cancer Research and Treatment|May 8, 2020
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015Peter H O'Donnell, Vassily Trubetskoy, Ashley Nurhussein-Patterson, et al.
Pageof 82